Investment case
bluebird bio, Inc.
BLUE · 9 developments mapped · last assessed 2026-09-24
Market Ontology has mapped 9 macro, policy, and market developments to bluebird bio, Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for BLUE yet, so no modelled value is shown. The BLUE valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run BLUE on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
Indirect benefit from overall market expansion and increased investor interest in cell therapy, potentially improving access to capital and future commercialization prospects for their gene therapy pipeline, which shares technological similarities and patient populations.
· Moves probability of success for pipeline assets, future market penetration for gene therapies
- Main threat
CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
Increased competitive pressure in the gene therapy market for blood disorders, potentially impacting market share or pricing power for competing therapies.
· Moves market share projections for zynteglo and lyfgenia, pricing power for gene therapies
- Open question
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Indirect competitive pressure and market dynamics for gene therapies in similar indications. Validation of gene therapy market but also increased competition.
· Moves market share for gene therapies, pricing
What changed, by assumption
- 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
- 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-24 | Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026 | watch | 3-12m | 0.25 |
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Bullish | 1-5y | 0.40 |
| 2026-09-12 | Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline | mixed | 1-3m | 0.20 |
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | watch | 1-5d | 0.20 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | mixed | 3-12m | 0.50 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+ | Bearish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | mixed | 3-12m | 0.40 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | mixed | 1-3m | 0.40 |
| 2026-09-01 | Valion Bio, Inc. Follow-On — $7.7M | watch | 3-12m | 0.20 |